BACKGROUND: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1-risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure has not been explored comprehensively. METHODS: The clinical characteristics and treatment outcome of 438 patients with low-risk and intermediate-1-risk MDS who were treated with HMAs were retrospectively analyzed. RESULTS: Using the International Working Group response criteria, the overall objective response to HMA was 35% with a median of 6 cycles of HMA administered, and the median response duration was 7 months. Only 7% of patients had disease that transformed into acute myeloid leukemia while receiving therapy. Of the 290 patients who were evaluable at the time of HMA failure, 77% remained in the lower-risk disease categories. On multivariate analysis, baseline neutropenia, intermediate-risk and poor-risk baseline karyotype, and lack of response to HMA were found to be independently associated with a higher risk of disease progression. With a median follow-up of 16 months, the median transformation-free survival and overall survival (OS) after HMA failure were 15 months and 17 months, respectively. On multivariate analysis, only The University of Texas MD Anderson Global Scoring System was found to be independently predictive of outcome, with patients with higher-risk categories having poor transformation-free survival (hazards ratio [HR], 1.5; P = .003) and OS (HR, 1.8; P = .002). The administration of salvage therapy was independently associated with better OS only (HR, 0.8; P = .01). CONCLUSIONS: Outcomes of patients with lower-risk MDS after HMA failure are poor and the treatment of these patients remains an unmet medical need. OS is a reasonable primary endpoint for clinical studies targeting this population.
BACKGROUND: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1-risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure has not been explored comprehensively. METHODS: The clinical characteristics and treatment outcome of 438 patients with low-risk and intermediate-1-risk MDS who were treated with HMAs were retrospectively analyzed. RESULTS: Using the International Working Group response criteria, the overall objective response to HMA was 35% with a median of 6 cycles of HMA administered, and the median response duration was 7 months. Only 7% of patients had disease that transformed into acute myeloid leukemia while receiving therapy. Of the 290 patients who were evaluable at the time of HMA failure, 77% remained in the lower-risk disease categories. On multivariate analysis, baseline neutropenia, intermediate-risk and poor-risk baseline karyotype, and lack of response to HMA were found to be independently associated with a higher risk of disease progression. With a median follow-up of 16 months, the median transformation-free survival and overall survival (OS) after HMA failure were 15 months and 17 months, respectively. On multivariate analysis, only The University of Texas MD Anderson Global Scoring System was found to be independently predictive of outcome, with patients with higher-risk categories having poor transformation-free survival (hazards ratio [HR], 1.5; P = .003) and OS (HR, 1.8; P = .002). The administration of salvage therapy was independently associated with better OS only (HR, 0.8; P = .01). CONCLUSIONS: Outcomes of patients with lower-risk MDS after HMA failure are poor and the treatment of these patients remains an unmet medical need. OS is a reasonable primary endpoint for clinical studies targeting this population.
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian Journal: Blood Date: 2006-04-11 Impact factor: 22.113
Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316
Authors: Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: G Garcia-Manero; J Shan; S Faderl; J Cortes; F Ravandi; G Borthakur; W G Wierda; S Pierce; E Estey; J Liu; X Huang; H Kantarjian Journal: Leukemia Date: 2007-12-13 Impact factor: 11.528
Authors: Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre Issa; Emil J Freireich; Guillermo Garcia-Manero Journal: Cancer Date: 2008-09-15 Impact factor: 6.860
Authors: David A Sallman; Rami S Komrokji; Kendra L Sweet; Qianxing Mo; Kathy L McGraw; Vu H Duong; Ling Zhang; Lisa Ann Nardelli; Eric Padron; Alan F List; Jeffrey E Lancet Journal: Leuk Res Date: 2019-03-30 Impact factor: 3.156
Authors: Moreno Festuccia; Kelsey Baker; Theodore A Gooley; Brenda M Sandmaier; H Joachim Deeg; Bart L Scott Journal: Biol Blood Marrow Transplant Date: 2017-06-30 Impact factor: 5.742